Trends in Cardiovascular Medicine
Volume 16, Issue 1 , Pages 15-20 , January 2006

Effects of Systemic Inflammation on Endothelium-Dependent Vasodilation

  • Alex L. Huang
    • ,
  • Joseph A. Vita

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Joseph A. Vita, MD, Section of Cardiology, Boston Medical Center, 88 East Newton Street, Boston, MA 02118, USA.

References 

  1. Anderson JL. Infection, antibiotics, and atherothrombosis—end of the road or new beginnings?. N Engl J Med. 2005;352:1706–1709
  2. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation. 2003;107:2409–2415
  3. Bhagat K, Moss R, Collier J, Vallance P. Endothelial “stunning” following a brief exposure to endotoxin: A mechanism to link infection and infarction?. Cardiovasc Res. 1996;32:822–829
  4. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering—are they clinically relevant?. Eur Heart J. 2003;24:225–248
  5. Brevetti G, Martone VD, De Cristofaro T, et al. High levels of adhesion molecules are associated with impaired endothelium-dependent vasodilation in patients with peripheral arterial disease. Thromb Haemost. 2001;85:63–66
  6. Brevetti G, Silvestro A, Di Giacomo S, et al. Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. J Vasc Surg. 2003;38:374–379
  7. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257–265
  8. Davis SF, Yeung AC, Meredith IT, et al. Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year posttransplant. Circulation. 1996;93:457–462
  9. Epstein SE, Zhu J, Burnett MS, et al. Infection and atherosclerosis: Potential roles of pathogen burden and molecular mimicry. Arterioscler Thromb Vasc Biol. 2000;20:1417–1420
  10. Fichtlscherer S, Rosenberger G, Walter DH, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation. 2000;102:1000–1006
  11. Fichtlscherer S, Rossig L, Breuer S, et al. Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation. 2001;104:3023–3025
  12. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348:593–600
  13. Hingorani AD, Cross J, Kharbanda RK, et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation. 2000;102:994–999
  14. Holmlund A, Hulthe J, Millgard J, et al. Soluble intercellular adhesion molecule-1 is related to endothelial vasodilatory function in healthy individuals. Atherosclerosis. 2002;165:271–276
  15. Hurlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation. 2002;106:2184–2187
  16. Husain S, Andrews NP, Mulcahy D, et al. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation. 1998;97:716–720
  17. Kharbanda RK, Walton B, Allen M, et al. Prevention of inflammation-induced endothelial dysfunction: A novel vasculo-protective action of aspirin. Circulation. 2002;105:2600–2604
  18. Kuvin JT, Gokce N, Holbrook M, et al. Effect of short-term antibiotic treatment on Chlamydia pneumoniae and peripheral endothelial function. Am J Cardiol. 2003;91:732–735
  19. Kuvin JT, Patel AR, Sliney KA, et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J. 2003;146:168–174
  20. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–1143
  21. Mitchell GF, Parise H, Vita JA, et al. Local shear stress and brachial artery flow-mediated dilation: The Framingham Heart Study. Hypertension. 2004;44:134–139
  22. Monaco C, Paleolog E. Nuclear factor kappaB: A potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res. 2004;61:671–682
  23. Oliver JJ, Webb DJ. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler Thromb Vasc Biol. 2003;23:554–566
  24. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511
  25. Pepys MB. CRP or not CRP? That is the question. Arterioscler Thromb Vasc Biol. 2005;25:1091–1094
  26. Pleiner J, Schaller G, Mittermayer F, et al. Simvastatin prevents vascular hyporeactivity during inflammation. Circulation. 2004;110:3349–3354
  27. Prasad A, Zhu J, Halcox JP, et al. Predisposition to atherosclerosis by infections: Role of endothelial dysfunction. Circulation. 2002;106:184–190
  28. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363–369
  29. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–126
  30. Sinisalo J, Paronen J, Mattila KJ, et al. Relation of inflammation to vascular function in patients with coronary heart disease. Atherosclerosis. 2000;149:403–411
  31. Stocker R, Keaney JF. The role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84:1381–1478
  32. Tan KC, Chow WS, Tam SC, et al. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2002;87:563–568
  33. Teragawa H, Fukuda Y, Matsuda K, et al. Relation between C reactive protein concentrations and coronary microvascular endothelial function. Heart. 2004;90:750–754
  34. Tomai F, Crea F, Gaspardone A, et al. Unstable angina and elevated C-reactive protein levels predict enhanced vasoreactivity of the culprit lesion. Circulation. 2001;104:1471–1476
  35. Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: Does acute endothelial dysfunction provide a link?. Lancet. 1997;349:1391–1392
  36. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913–919
  37. Verma S, Wang CH, Lonn E, et al. Cross-sectional evaluation of brachial artery flow-mediated vasodilation and C-reactive protein in healthy individuals. Eur Heart J. 2004;25:1754–1760
  38. Vita JA. Nitric oxide-dependent vasodilation in human subjects. Methods Enzymol. 2002;359:186–200
  39. Vita JA, Keaney JF, Larson MG, et al. Brachial artery vasodilator function and systemic inflammation in the Framingham Offspring Study. Circulation. 2004;110:3604–3609
  40. Widlansky ME, Gokce N, Keaney JF, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42:1149–1160
  41. Widlansky ME, Price DT, Gokce N, et al. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension. 2003;42:310–315
  42. Witte DR, Broekmans WM, Kardinaal AF, et al. Soluble intercellular adhesion molecule 1 and flow-mediated dilatation are related to the estimated risk of coronary heart disease independently from each other. Atherosclerosis. 2003;170:147–153

PII: S1050-1738(05)00204-5

doi: 10.1016/j.tcm.2005.10.002

Trends in Cardiovascular Medicine
Volume 16, Issue 1 , Pages 15-20 , January 2006

Article Tools